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The Changing Face of Heart Transplantation
Sharon A. Hunt, MD, FACC, François Haddad, MD, FRCPC
Palo Alto, California
It has been 40 years since the first human-to-human heart transplant performed in South Africa by Christiaan
Barnard in December 1967. This achievement did not come as a surprise to the medical community but was the
result of many years of early pioneering experimental work by Alexis Carrel, Frank Mann, Norman Shumway, and
Richard Lower. Since then, refinement of donor and recipient selection methods, better donor heart manage-
ment, and advances in immunosuppression have significantly improved survival. In this article, we hope to give a
perspective on the changing face of heart transplantation. Topics that will be covered in this review include the
changing patient population as well as recent advances in transplantation immunology, organ preservation, allo-
graft vasculopathy, and immune tolerance. (J Am Coll Cardiol 2008;52:587–98) © 2008 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.05.020r
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rt has been 40 years since the first human-to-human heart
ransplant performed in South Africa by Christiaan Barnard
n December 1967 (1). This achievement did not come as a
urprise to the medical community but was the result of
any years of early pioneering experimental work by Alexis
arrel, Frank Mann, Norman Shumway, and Richard
ower (2–4). Media attention surrounding the first heart
ransplants was enormous as each patient’s daily progress
as followed very closely and reported worldwide (1). The
rst heart transplant patient, Mr. Washkansky, had a good
arly recovery but unfortunately died of pneumonia 18 days
ater. The second heart transplant patient, Mr. Blaiberg, was
he first patient to leave the hospital and returned to a
elatively normal life. It was Mr. Blaiberg’s success perhaps
ore than any other factor that led to guarded optimism
hat heart transplantation would eventually prove to be a
aluable treatment option (2).
This initial enthusiasm was, however, quickly curbed
hen it became evident that survival was usually measured
n terms of days or weeks (1). Inadequate understanding of
arly post-operative complications as well as a lack of tools
o address the problems of acute rejection and opportunistic
nfection led to initially poor results. Allograft vasculopathy
s a cause of graft failure and death was also recognized
hen Mr. Blaiberg sadly died of a myocardial infarction 19
onths after his heart transplantation. This came as a
urprise to the medical profession, which had not antici-
ated that coronary artery disease in a transplanted heart
ould progress so rapidly (2).
rom the Division of Cardiovascular Medicine, Stanford University, Palo Alto,
alifornia.w
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ccepted May 20, 2008.Over the next 2 decades, refinement of donor and
ecipient selection methods, better donor heart manage-
ent, and the introduction of cyclosporine as the main
mmunosuppressive agent significantly improved survival.
ith a 1-year survival approaching 90%, a 5-year survival
ate of approximately 70%, and a median survival in excess
f 10 years, heart transplantation is now a valuable option
or selected patients with end-stage heart failure (Fig. 1) (5).
he field of heart transplantation is constantly evolving.
dvances in organ preservation, immune monitoring, and
mmunosuppressive regimens are likely to lead to further
mprovement in the quality and the length of life of heart
ransplant recipients (Fig. 1). In this article, our objective is
o give a perspective on the changing face of heart trans-
lantation. Topics that will be covered include the changing
atient population as well as recent advances in transplan-
ation immunology, organ preservation, allograft vasculopa-
hy, and immune tolerance.
he Changing Patient Population
he face of heart transplantation is slowly changing. At the
ame time as older patients are being considered for heart
ransplantation, a greater proportion of younger patients
eing referred for evaluation have complex congenital heart
isease (CHD) (3,5). There is also a slow increase in both
he number of patients who require mechanical circulatory
upport (MCS) as a bridge to transplantation and the
umber of retransplant candidates (5). This changing pa-
ient population brings new challenges to the transplant
hysicians. Among them, the risk of having preformed
ntibodies directed against the donor heart (sensitized
atients) is particularly challenging as it may increase the
isk of rejection and allograft vasculopathy (5–7). Patients
ith CHD often have a more complex anatomy and are also
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tive bleeding and mortality (8).
Once considered an absolute
contraindication to transplanta-
tion, older recipient age is now
seen as a relative contraindication
(9). Older recipient age is usually
considered a risk factor for re-
duced post-transplant survival,
although many single-center
studies report excellent survival
in carefully selected older recipi-
ents (9,10). The incidence of re-
jection is usually lower in older
recipients while the incidence of
infection and allograft vasculopa-
thy appears to be higher (5,9).
With the advances made in
cardiac surgery, an increasing
umber of patients with CHD are now surviving into
dulthood. Many patients with CHD develop heart failure
ater in life, despite repair or palliation or as a result of
ncorrected lesions (8,11). The most common congenital
esions in patients referred for transplantation include trans-
osition of great arteries with a failing right ventricle, failed
ontan procedures, palliated single ventricle, Ebstein’s
nomaly, and tetralogy of Fallot with severe right ventricular
ysfunction (8,11). According to the International Society
or Heart and Lung Transplantation (ISHLT) database,
Abbreviations
and Acronyms
AMR  antibody-mediated
rejection
CHD  congenital heart
disease
CNI  calcineurin inhibitor
GEP  gene expression
profiling
HLA  human leukocyte
antigen
ISHLT  International
Society for Heart and Lung
Transplantation
MCS  mechanical cardiac
support
RF  renal failure
Figure 1 Historical Perspective of Heart Transplantation
The figure describes the major landmarks of heart transplantation associated with
in survival. FDA  Food and Drug Administration; MMF  mycophenolate mofetil.HD is identified as one of the strongest risk factors for
-year mortality after heart transplantation in adults (5,8).
n contrast, in those who survive 3 years, CHD disease has a
0-year survival advantage independent of age. Factors that
ay contribute to this earlier mortality include: 1) adhesions
rom prior surgeries; 2) a higher incidence of collateral vessels,
hich increases the risk of bleeding; 3) technically more
hallenging surgery because of the unusual anatomy; and
) a higher incidence of sensitized patients. The risk of
arly mortality may also be different according to the
nderlying pathology, with more favorable outcomes for
imple uncorrected lesions than for complex uncorrected
esions.
In the last decade, there has also been an increase in the
umber of patients requiring MCS as a bridge to transplan-
ation (12). This technology has allowed many severely ill
dult and pediatric patients to survive until a suitable donor
eart became available. Patients who require MCS are at
ncreased risk for rejection, infection, stroke, and bleeding.
he need for transfusions and possibly the mechanical
evices themselves increase the risk of pre-sensitization
5–7). Based on the ISHLT database, survival at 1 and 5
ears is decreased in patients requiring MCS but still higher
han 80% and 70%, respectively (5).
With the increasing number of patients transplanted at
arly ages, it is also expected that the need for retransplan-
ation will become more common in the future. For now,
owever, retransplantation comprises only a small minority
3%) of heart transplants (5). Overall survival rates for
ssive improvement
d, with permission, from Hunt (1).progre
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August 19, 2008:587–98 Heart Transplantationetransplant patients are significantly lower than for other
ransplant patients, possibly reflecting an increased risk of
llosensitization as well as the consequence of years of
mmunosuppression (5,13,14). Risk factors for poor out-
ome include retransplantation early after primary trans-
lantation (6 months), retransplantation for acute rejec-
ion, or early allograft failure and retransplantation in an
arlier era (13,14). When selection criteria for retransplan-
ation excluded retransplantation for primary allograft fail-
re and intractable acute rejection occurring less than 6
onths after transplantation, 1-, 2-, and 4-year survival
ates after retransplantation were comparable to those after
rimary transplantation (13,14).
dvances in Donor Allocation and Selection
n the U.S., the organization United Network for Organ
haring is contracted by the federal government to regulate
onor heart allocation and has a priority system that is based
n the severity of cardiac illness, geographic distance be-
ween donor and recipient, length of time on the waiting
ist, and ABO blood group compatibility (11). At the
urrent time, the physiological limit of approximately 4 to
h of ischemic time precludes a national sharing of donor
earts or matching donor hearts according to human leu-
ocyte antigen (HLA) compatibility (10). The algorithm for
llocation of donor hearts used by the United Network for
rgan Sharing was changed in January 1999 to better
ccount for medical urgency and to decrease waiting times
or blood type O recipients (15). Medical urgency is 2-tiered
n the 1989 system and 3-tiered in the new system; the new
llocation algorithm also allows an individual with life-
hreatening ventricular arrhythmias to be listed in the
ighest urgency status (15). In recent years, the widening
ap between the number of waiting recipients and the
umber of donors has resulted in a continuing trend toward
ransplanting urgent status recipients and to a liberalization
f donor acceptance criteria (16). Despite these changes,
ost-transplant survival has remained constant mainly due
o advances in treatment (16).
Donor heart acceptance is a 2-phase process. The first
tep is to rule out any contraindication to heart donation
uch as significant heart dysfunction, CHD, transmissible
iseases, or malignancies (except primary tumors of the
entral nervous system with low metastastic potential).
he second step is to match a specific donor to a suitable
ransplant candidate. In heart transplantation, matching
s based on ABO blood group compatibility (not identity)
nd compatibility of body size. Although adult donor
earts must be ABO compatible with the recipient, this
oncept has been recently challenged in infants (age 12
onths) by the successful performance of ABO incompat-
ble heart transplants (11,17). In their landmark study, West
t al. (17) have shown that in infants serum titers as well as
roduction of anti-A and anti-B antibodies are usually low
nough to allow transplantation with ABO incompatible fonor hearts. Matching donor and recipient for size is
specially important in patients with pulmonary hyperten-
ion. In general, a height and weight difference of up to 20
ercent is tolerated; in potential recipients with significant
ulmonary hypertension, donor size equal or higher than
he recipient is usually recommended. In pediatric patients,
n order to address donor shortage, a more liberal strategy
tilizing an oversized donor has been advocated by many
enters with successful results (11).
Donor characteristics that have been associated with
utcome include age, left ventricular hypertrophy, and
ender mismatches. The use of older donor hearts (40
ear old) is associated with higher perioperative mortality
nd a higher incidence of later cardiac allograft vasculopathy
5). Donor left ventricular hypertrophy, defined by a left
entricular wall thickness greater than 14 mm has also been
ssociated with decreased long-term survival in some studies
18). Recent studies have also called attention to gender
ismatch in cardiothoracic transplantation. According to
he ISHLT database, female donor gender is associated
ith worse 5- and 10-year survival in male recipients (5).
onor heart allocation from hepatic C positive patients is
lso sometimes considered for recipients on an alternate list.
recent study from the U.S. Scientific Registry of Trans-
lant Recipients has demonstrated that donor hepatitis C
irus status is associated with a decrease in 1- and 5-year
ortality in recipients older than 39 years irrespective of
ecipient hepatitis C virus status (19).
According to the ISHLT registry, high center volume is
ssociated with better post-transplant outcomes (5). In an
ffort to improve survival, the federal regulatory agencies
etermined that a heart transplant program must do at least
2 transplants per year to receive federal reimbursement,
ccording to the Centers for Medicare and Medicaid
ervices.
dvances in Surgical
echnique and Organ Preservation
he surgical techniques for heart transplantation include 2
asically different surgical approaches (i.e., orthotopic [the
onor heart implanted in the normal place of the native
eart] and heterotopic [donor heart implanted beside the
ative heart]) (20,21).
The biatrial technique for orthotopic heart transplanta-
ion was first introduced in a dog model by Lower and
humway in 1960 (22). Preservation was provided by the
se of topical hypothermia induced by immersion of the
raft in iced saline (3,22). In 1991, Sievers et al. (23)
escribed a variation of the orthotopic procedure termed the
icaval technique where the donor right atrium is attached
irectly to the inferior and superior vena cava and the left
trial anastomosis is done as a cuff. Compared with the
lassical biatrial approach, the bicaval approach results in
ess disruption of the atrial geometry, better right ventricular
unction, less tricuspid and mitral regurgitation, and less
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Heart Transplantation August 19, 2008:587–98inus node dysfunction (24). Despite increasing use of the
icaval technique, tricuspid regurgitation remains a problem
arly and late after heart transplantation. Adding a tricuspid
nnuloplasty to the transplant operation has been recently
hown to decrease the incidence of tricuspid regurgitation
nd may even improve survival (25).
Heterotopic heart transplantation was first performed by
arnard in 1974 as a left ventricular bypass and involves
lacing a donor heart in the right lower thorax where it is
nastomosed to work in parallel to the recipient heart,
hich is left intact (2). The concept of having the donor and
ative heart side by side was more appealing in the early era
f heart transplantation when the incidence of early graft
ailure was high. Although rarely done today, there remain
possible indications for heterotopic heart transplantation:
) patients with elevated pulmonary hypertension in whom
he donor right ventricle would be unable to tolerate the
ncreased afterload; and 2) significant size mismatch (donor/
ecipient weight ratio 75%), especially seen in pediatric
atients. Heart-lung transplantation may also represent an
ption for patients with irreversible elevation in pulmonary
ypertension.
Figure 2 Steps in T Cell Activation
The alloimmune response often requires activation of multiple signaling pathways. The
receptor. Costimulation (signal 2) occurs when CD80 (B7-1) and CD86 (B7-2) on the a
pathways (calcineurin, RAS-mitogen-activated protein kinase [MAP-K] pathway, and the
molecules, including interleukin (IL)-2 and IL-15. Interleukin-2 and other cytokines then
nal 3). AP-1  activating protein 1; CDK  cyclins-dependent protein kinase; IKK  se
 messenger ribonucleic acid; mTOR  mammalian target of rapamycin; NFAT  nuc
TCR  T cell receptor. Adapted, with permission, from Halloran (28).Recent advances in organ preservation may also lead to
urther improvement in outcomes. One of the most prom-
sing new technologies is normothermic organ preservation,
hich provides warm blood perfusion of the donor organ,
otentially decreasing reperfusion injury and graft dysfunc-
ion. If proven effective, this technology may decrease early
raft failure and allow increased utilization of available
rgans. Its potential to decrease ischemic time may also give
reater opportunity for prospective cross-matching in heart
ransplantation (26).
dvances in Immunology
mmunologic barriers remain the central issue in transplan-
ation medicine. An evolving understanding of the pathways
nvolved in immune activation has led to many break-
hroughs in transplantation medicine, including the devel-
pment of many novel immunosuppressive agents. In this
ection, we will review the pathways involved in the allo-
mmune response, the principles of immune monitoring, as
ell as recent advances in immunosuppressive therapies.
ignal is provided when antigen-presenting cells and antigens activate the T cell
-presenting cells engage CD28. Both signals activate important signal transduction
ar factor-kappa B [NF-kB] pathway). These pathways lead to the expression of many
te the “target of rapamycin” pathway to provide the trigger for cell proliferation (sig-
reonine protein kinase; JAK3  Janus kinase 3; MHC  myosin heavy chain; mRNA
ctor of activated T cells; PKC  protein kinase C; S-1-P  sphingosine-1-phosphate;first s
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August 19, 2008:587–98 Heart Transplantationhe alloimmune response. T cell lymphocyte activation
lays a central role in the alloimmune response (Fig. 2).
oth naïve and memory lymphocytes may be involved,
ncluding memory lymphocytes that may have been previ-
usly stimulated by viral antigens that can cross-react with
LA antigens (27,28). The alloimmune response usually
tarts with the activation of antigen-presenting cells of
onor (usually dendritic cells) and host origin. Once acti-
ated in the graft and surrounding tissue, these cells migrate
o secondary lymphoid organs where they may engage
lloantigen reactive naïve T cells and central memory T cells
28,29). Naïve T cells and memory T cells may recirculate in
he secondary lymphoid organs or undergo clonal expansion
nd differentiation into effector cells when activated. Some
irect antigen presentation to antigen-experienced cells by
onor cells such as graft endothelium may also occur
28,30).
In recent years, it has become clear that T cell activation
equires the stimulation of multiple signaling pathways. At
east 3 signals seem to be required to cause an effective
lloimmune response (Fig. 2) (28). The first signal origi-
ates from the interaction between the major histocompat-
bility complex/peptide complex and the T cell receptor/
D3 complex. Antigen-presenting cells, especially dendritic
ells, provide costimulation when the CD80 and CD86
B7) interact with the CD28 on T cells. Costimulation is
lso influenced by the interaction of CD80 and CD86 with
D152 (CTLA-4) as well as the interaction of CD40 and
D154 (CD40 ligand). These signals lead to the activation
f 3 transduction pathways: the calcium calcineurin path-
ay, mitogen-activated protein kinase pathway, and the
uclear factor-kappa B pathway (28,31). The activation of
hese pathways, in turn, leads to the expression of cytokines,
amely interlukin-2 as well as many molecules such as
D154 and CD25. The third signal of the alloimmune
esponse occurs when interleukin-2 and other cytokines
ctivate the target of rapamycin pathway that leads to cell
roliferation and differentiation and, therefore, a large
umber of effector cells.
B cells are activated when antigens interact with B cell
eceptors, usually in secondary lymphoid organs and possi-
ly in the transplant organ. B cell activation is also mediated
hrough the interaction between B and T cells through
D40/CD40L and B71-2/CD28 as well as CTLA-4– and
D20-mediated activation. Complement and inflammatory
ediators are also activated and contribute to the alloim-
une response (28).
ardiac rejection. There is growing acceptance that rejec-
ion, an immune-mediated allograft injury, may be caused
y both cellular- and antibody-mediated processes (32–34).
ecent studies suggest that antibody-mediated rejection
AMR), also known as humoral rejection, is associated with
ore severe hemodynamic compromise at presentation and
greater risk of allograft vasculopathy and mortality (33,34).
In cellular rejection, effector T cells mediate an inflam-
atory response that leads to infiltration of the myocardium uy activated macrophage, effector T cells, and plasma cells.
he characteristic lesion of cellular rejection represents
ononuclear cells invading the myocardium. Cellular rejec-
ion is classified into 3 classes depending on the extent of
ellular infiltration and myocyte damage. In the internation-
lly accepted grading system for cellular rejection, grade 2R
previously 3A) or higher is considered clinically significant
ellular rejection (35,36).
Antibody-mediated rejection occurs when alloantibody
gainst donor antigens targets capillary endothelium (32–
4). Although the significance of AMR is increasingly
ecognized, no firm consensus has yet been reached on its
ecognition and diagnosis either histopathologically or im-
unologically (36). Antibody-mediated rejection is usually
iagnosed histologically by demonstration of capillary injury
ith endothelial cell swelling and intravascular macrophage
ccumulation. Positive immunofluorescence or immunoper-
xidase staining for AMR (positive CD68, C4d, or C3d
omplement fragments) further supports the diagnosis (36).
merging literature also suggests that positive immuno-
uorescence for both C4d and C3d complement frag-
ents may be associated with clinical allograft dysfunc-
ion (37).
dvances in immunosuppression. The goal of immuno-
uppression is to prevent or treat rejection while minimizing
he risk of infection or cancer. In general, immunosuppres-
ion may be achieved by blocking lymphocyte activation or
esponse pathways, depleting lymphocytes, or diverting
ymphocytic traffic (28,38). The success of heart transplan-
ation has been closely related to the discovery of effective
mmunosuppressive regimens. In the early 1980s, the intro-
uction of cyclosporine as the mainstay of immunosuppres-
ive regimens was followed by a significant improvement in
urvival of heart transplant recipients (Fig. 1). Since then,
ther agents have been introduced, and several studies have
ried to answer important questions concerning immuno-
uppression (e.g., the need for early induction therapy, the
est combination of immunosuppressive agents, the safety
f early withdrawal of steroids, and the lowest possible
aintenance dose of immunosuppression) (Table 1).
Induction therapy refers to the use of more intense
mmunosuppression in the initial days after transplantation.
he rationale of induction therapy is to provide more
ntensive immunosuppression at the time when the alloim-
une response is most intense. It may also be used to permit
elayed initiation of calcineurin inhibitors (CNIs) for main-
enance immunosuppression in patients with significant renal
ailure (RF). Agents used for induction may be divided into 2
ategories: 1) depleting antibodies (e.g., polyclonal antibodies
horse or rabbit antithymocyte globulin], anti-CD3 antibodies
OKT3], human monoclonal anti-CD52 [alentuzumab]); or
) nondepleting antibodies or fusion proteins (e.g., anti-CD25
ntibodies [daclizumab, basiliximab] or fusion proteins with
atural binding properties currently being studied, e.g.,
TLA4-Ig [LEA29Y]) (39). Although induction therapy is
sed by approximately one-half of transplant programs, a
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Heart Transplantation August 19, 2008:587–98urvival benefit attendant on its use has not been clearly
stablished (39 – 41). Also, concerns about the long-term
omplications have been suggested by studies linking
KT3 use with a greater risk of lymphoproliferative
isorders (39,42). At this time, the weight of the evi-
ence may support a selective use of induction agents in
ighly sensitized patients or patients with severe RF at the
ime of transplantation.
The goal of maintenance immunosuppression is to
chieve host-graft adaptation while minimizing the risk of
nfection or cancer. Most cardiac transplant programs use a
riple therapy for maintenance immunosuppression consist-
ng of corticosteroids (usually prednisone), a CNI (cyclo-
porine or tacrolimus), and an antiproliferative agent (usu-
lly mycophenolate mofetil) (Table 2). Prednisone is used
arly after heart transplantation and usually tapered to low
oses or withdrawn during the first year. There are 2 general
pproaches to steroid withdrawal: early withdrawal within
he first month after transplantation or late withdrawal
etween 6 to 12 months post-transplant. Late steroid
ithdrawal may have the advantage of maintaining more
ntensive therapy in the first 6 months when the risk of
ejection is still high (11,43,44). There is particularly strong
nterest in minimizing steroid use in children, as it may
Immunosuppressive Agents in Heart Transplanta
Table 1 Immunosuppressive Agents in Hear
Immunosuppressive Agent Targ
Glucorticosteroid Multiple targets
of APC and n
Calcineurin inhibitors
Cyclosporine Cyclophilin
Tacrolimus FKBP12
Mycophenolate mofetil Purine synthes
Proliferation signal inhibitors
Sirolimus
Target-of-rapam
Everolimus (not yet FDA approved)
Polyclonal antibody: horse or rabbit
antithymocyte globulin
Depleting antib
Rituximab B-cell–depleting
CD20 antibo
Daclizumab, basiliximab Anti-CD25 antib
Alemtuzumab Anti-CD52 antib
Intravenous immunoglobulin Multiple sites o
interference
the cells of t
reticuloendo
CTLA-4-Ig (LEA29Y) (fusion protein) Costimulation s
APC  antigen-presenting cell; FDA  Food and Drug Administration.mpair normal growth. *The use of tacrolimus in heart transplantation has steadily
ncreased, and it now is the most commonly used CNI
5,45). In comparing CNIs, tacrolimus is associated with a
ecreased incidence of rejection episodes, although a sur-
ival benefit has not been clearly demonstrated (46). Most
rograms, however, individualize the choice of CNI de-
ending on the risks profile of the patient. Tacrolimus is
avored in the presence of a higher risk of rejection,
splantation
ss Comment
ing inhibition
transcription
Usually weaned during the first year
Cyclosporine favored in patients with
poorly controlled diabetes
mellitus; tacrolimus may be
associated with decreased
rejection episodes
itors Has replaced azathioprine in
combination regimens
Sirolimus may reduce the
progression of allograft
vasculopathy and malignancy;
associated with poor wound
healing
against T cells Selective use in the treatment of
severe cellular rejection or in
induction therapy
clonal anti- Selective use in the treatment of
humoral rejection
Selective use for induction therapy
Selective use for induction therapy
(preliminary experience in heart
transplantation), case reports of
its use in refractory rejection
ns including
c receptors on
system
Selective use in the treatment of
humoral rejection or sensitized
patients
nhibitor In phase III trials in renal
transplantation
aintenance Regimenssed in Heart Transplantation
Table 2 Maintenance RegimensUsed in Heart Transplantation
Regimens* Indication or Characteristic
Calcineurin inhibitor and mycophenolate
mofetil
Most common regimen used; older
transplant patients may still be
on a calcineurin inhibitor and
azathioprine combination
Calcineurin inhibitor and proliferation
signal inhibitor
Regimen often considered in
patients with established
allograft vasculopathy or
malignancy
Mycophenolate mofetil and proliferation
signal inhibitor
Calcineurin-free regimen
considered in patients with
severe renal insufficiency
Tacrolimus monotherapy Preliminary data suggest the safety
of tacrolimus monotherapy in
heart transplantation (45)tion
t Tran
et Cla
includ
uclear
is inhib
ycin
odies
mono
dy
ody
ody
f actio
with F
he
thelial
ignal iCorticosteroids usually part of all regimens during the first year.
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August 19, 2008:587–98 Heart Transplantationre-existing hypertension, or hyperlipidemia, while cyclo-
porine is favored in the presence of diabetes mellitus. The
se of mycophenolate mofetil has replaced the use of
zathioprine, which was the first immunosuppressive agent
o achieve widespread use in heart transplantation (1). More
ecently, target of rapamycin inhibitors or proliferation
ignal inhibitors (sirolimus and everolimus) have been
hown to decrease the progression of allograft vasculopathy
nd cancer as well as provide resistance to rejection (47–49).
oor wound healing is, however, a side effect associated with
irolimus and probably to a lesser degree with everolimus
50). In patients with established allograft vasculopathy,
irolimus has been demonstrated to decrease the progression
f allograft vasculopathy and occasionally leads to some
eversal of the process (48,51). In patients with severe RF,
alcineurin-free regimens (combining sirolimus and myco-
henolate mofetil) late after transplantation can improve
enal function without increasing the risk of rejection
52,53). A recent study also suggests that belatacept, a
ostimulatory signal inhibitor (previously referred to as
EA29Y), could represent an alternative to CNIs (54). In a
hase II multicenter noninferiority trial in de-novo renal
ransplant recipients, Vincenti et al. (54) showed that there
as no significant difference in acute rejection rates between
elatacept and cyclosporine. Interestingly, belatacept-
reated patients demonstrated significantly lower rates of
ubular atrophy and interstitial fibrosis. Phase III clinical
rials of belatacept are ongoing in renal transplantation. If
roven efficacious and safe, belatacept will most probably
ndergo study in heart transplantation. Also, individualiza-
ion of immunosuppression with better immune monitoring
nd pharmacogenomics will eventually play a greater role in
ptimization of therapy (55).
Methods for managing acute rejection are also evolving.
n general, the management strategy for acute rejection
epends on the histological type of rejection (cellular vs.
MR) as well as its severity (hemodynamic compromise
nd/or high histological grade). A high-dose corticosteroid
3-day course of methylprednisolone 1 g daily) is used for
ignificant cellular rejection (2R in the new ISHLT
lassification) or any rejection-associated hemodynamic
ompromise. Lymphocyte-depleting agents such as antithy-
ocyte globulin are also considered in patients with hemo-
ynamically compromising or high-grade (3R) cellular re-
ection. As clinical experience is increasing, the treatment of
MR is being better defined (34). Severe hemodynamically
ompromising AMR is usually treated with high-dose
orticosteroids and plasmapheresis followed by intravenous
mmunoglobulin or rituximab (a B-cell–depleting monoclo-
al anti-CD20 antibody). T cell depleting antibodies such
s antithymocyte globulin are sometimes added to help
odulate the interaction of T and B cells. Studies assessing
he best treatment strategy for AMR are currently in
rogress.
Patients with recurrent rejection are particularly challeng-ng to manage. A recent study by Kirklin et al. (56) has dhown that the technique of photopheresis may reduce the
isk of subsequent hemodynamic compromise rejection
nd/or death from rejection when initiated for patients with
igh rejection risk. Total lymphoid irradiation has also been
hown to decrease the chances of subsequent rejection but
ay be associated with a greater risk of lymphoproliferative
isorders (57).
he Changing Face
f Immune and Functional Monitoring
urrent immune monitoring of cardiac transplants is im-
erfect and revolves around the use of the endomyocardial
iopsy, drug level monitoring, and echocardiography. Al-
hough this strategy has proven to be very useful, many
atients still present with rejection, infection, or drug
oxicity despite having the desired level of immunosuppres-
ion. Although endomyocardial biopsy is the time-honored
old standard for the diagnosis of rejection, its value may be
imited by significant interobserver variability, sampling
rror, and the difficulty in interpreting nodular endocardial
nfiltrates (Quilty lesions) (36,58). There is also a wide
ariability in frequency and duration of surveillance endo-
yocardial biopsy, with most centers now limiting routine
ndomyocardial biopsies to 5 years (59).
An ideal immune monitoring strategy would be nonin-
asive, reliably allow discrimination between the presence
nd absence of rejection, and detect a state of overimmu-
osuppression. Such a strategy does not currently exist. A
omprehensive monitoring strategy will most probably rely
n a combination of multiple monitoring tools. These
onitoring tools may include: 1) current invasive biopsy
ith histopathology; 2) monitoring of graft function with
maging modalities and B-type natriuretic peptide (BNP); 3)
rug level monitoring; 4) genomic markers of rejection; 5)
onor-specific antibodies monitoring; and 6) direct immune
unction assays (Table 3).
In the last 20 years, many studies have demonstrated that
bnormal diastolic parameters of allograft function represent
ensitive, although less specific, markers of cellular rejection
60,61). In a recent study, Dandel et al. (60) have shown
hat a 10% change in maximal systolic or diastolic tissue
oppler velocity of the posterior wall of the left ventricle
as a sensitive and specific marker of cellular rejection
grade2 in the previous classification). Validation of these
ndings is currently underway in several institutions. Ele-
ation in BNP was also associated with cellular rejection in
everal studies, although a cutoff value with clear discrimi-
ant capacity has not been determined (62). Experience
rom the echocardiography literature suggests that dynamic
hanges in BNP may prove to be more valuable than
bsolute values.
In clinical practice, drug monitoring of CNIs, mycophe-
olate mofetil, and proliferation signal inhibitors is usually
ased on trough drug levels. Although logistically more
ifficult, several studies have shown that peak measurements
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Heart Transplantation August 19, 2008:587–98f drug levels of medication may better reflect the area under
he curve of immunosuppressive drugs (63–65). More
omprehensive pharmacokinetics may also allow the iden-
ification of inconstant absorbers, which could lead to
urther refinement in drug dosing (63).
Gene expression profiling (GEP) is also bringing new
nsight into the mechanisms involved in rejection (66–68).
enes that are activated during acute cellular rejection
nvolve a wide range of pathways, including T cell activation
nd trafficking, natural killer-cell activation, stem cell mo-
ilization, hematopoiesis, alloimmune recognition, and ste-
oid responsiveness (67,68). Gene expression profiling may
lso be useful for rejection surveillance in heart transplant
ecipients. In the CARGO (Cardiac Allograft Rejection
ene Expression Observation) study, a multigene algorithm
ased on the expression of 20 genes (11 informative, 9
ontrol genes) was developed and validated. The algorithm
eighs the contribution of each gene and results in a score
anging from 0 to 40, with scores below threshold indicating
very low likelihood of moderate-to-severe acute cellular
ejection on endomyocardial biopsy (ISHLT grade 3A/
R). In the CARGO study, using a threshold of 20, the test
ad a sensitivity for rejection of 84% (95% confidence
nterval: 66% to 94%) and the specificity was 38% (95%
onfidence interval: 22% to 56%) (66,68). The threshold of
he test was later increased to 34 to improve its sensitivity.
his test has not yet become a major part of clinical practice
ecause further information is needed to assess the safety of
outine GEP instead of biopsies (ongoing IMAGE [Inva-
Immune and Functional Monitoring of Heart Tra
Table 3 Immune and Functional Monitoring
Monitoring Tool Type
Endomyocardial biopsy Histology and immunoh
Drug monitoring and
pharmacogenomics
Drug level or AUC
Functional monitoring Diastolic parameters
Tissue Doppler
BNP
Genomic markers of rejection AlloMap* gene expressi
test
T cell functional assays 1) ImmuKnow
2) Elispot
Antibody monitoring DSA
*XDx, Brisbane, California.
AMR  antibody-mediated rejection; AUC  area under the curve; Bive Monitoring Attenuation Through Gene Expression] ttudy) (68). Also, importantly, a gene expression profile that
istinguishes AMR from the nonrejecting state has yet to be
eveloped.
Direct immune assays that monitor antibody production
nd T cell function are also finding their way into clinical
ractice (6,69,70). At this time, however, no current test is
oth practical and specific enough to predict under- or
verimmunosuppression (71). The detection of anti-HLA
onor-specific antibodies has been associated with an in-
reased incidence of early and severe allograft rejection and
ith the late development of cardiac allograft vasculopathy
nd decreased survival (6,72,73). The importance of non-
LA antibodies is also being increasingly recognized (6).
lthough HLA sensitization is a well-recognized risk factor
or worse outcomes, the benefit of treating hypersensitized
atients with normal graft function is at this time not clearly
stablished. A recent assay of T cell function has also
een recently introduced (ImmuKnow, Cyclex Inc., Co-
umbia, Maryland). The assay measures the amount of
denosine triphosphate production by CD4 T cells
solated from whole blood and stimulated by phytohe-
agglutinin. In an observational study, transplant pa-
ients with rejection had, on average, higher values, while
hose without rejection had lower values. A recent
rospective study presented by Jon Kobashigawa at the
SHLT annual meeting (74) suggested that ImmuKnow
evels are associated with rejection or infection risk. Future
rospective studies are, however, needed to assess the value
f ImmuKnow and other functional T cells assays in heart
nt Recipients
art Transplant Recipients
Value
mistry Time-honored gold standard for the diagnosis
of rejection; disadvantage of being invasive
and susceptible to sampling errors and
variability in interpretation
Trough levels are usually monitored for
practical reasons although peak levels
usually correlate better with AUC; gene
polymorphisms of CYP3A5 and MDR1
correlate with calcineurin inhibitor levels
Moderate correlation with significant rejection
 tissue Doppler systolic velocities are
sensitive although less specific for the
diagnosis of significant rejection
Correlates with significant rejection; no specific
threshold has good discrimination capacity
filing Sensitive marker for cellular rejection although
lower specificity; not validated for AMR
Marker of T cell activation, currently under
validation in heart transplantation
Marker of cytokine-producing T cells;
currently under validation
The presence of DSA has been associated
with an increased risk of rejection and
allograft vasculopathy
B-type natriuretic peptide; DSA  donor-specific antibodies.nspla
of He
istoche
on proransplantation (70).
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ransplant allograft vasculopathy represents the most com-
on cause of late graft failure. Beyond the first year,
ransplant vasculopathy and malignancy are the 2 most
mportant causes of death (5). Significant allograft vascu-
opathy, defined angiographically by a diameter stenosis
reater than 50%, is found in approximately 30% to 50% of
atients at 5 years (5,7). Compared with atherosclerotic
oronary artery disease, allograft vasculopathy is usually
haracterized by diffuse intimal hyperplasia that may affect
he epicardial vessels as well as the microcirculation in a
ongitudinal and concentric fashion (7,75–77). Plaque rup-
ure is uncommon in allograft vasculopathy because of its
sually diffuse and hyperplasic nature (7,75–77).
Understanding of allograft vasculopathy has progressed
ignificantly in the last 10 years, although the exact patho-
hysiological mechanisms involved are still incompletely
nderstood (7,76,77). Several immune and nonimmune risk
actors have been identified. Nonimmune risk factors in-
lude hyperlipidemia, hypertension, diabetes mellitus, hy-
erhomocysteinemia, older donor age, and explosive etiol-
gy of donor brain death (5,78,79). Immune risk factors
nclude HLA donor/recipient mismatches (especially HLA
R mismatches), recurrent cellular rejection, and AMR
33,61,78). The role of viral infections, especially cytomeg-
lovirus infection, in the progression of allograft vasculopa-
hy is also being increasingly recognized (80). Recent studies
ave shown that patients with cytomegalovirus infection,
hether symptomatic or not, more frequently have allograft
asculopathy, which also may be more severe (80). Recent
tudies also suggest that donor and recipient hepatitis B and
onor hepatitis C may be associated with an accelerated
orm of allograft vasculopathy (79).
Intravascular ultrasound is playing a greater role in the
iagnosis and follow-up of allograft vasculopathy (79,81).
y intravascular ultrasound criteria, allograft vasculopathy is
sually defined as an intimal thickness 0.5 mm. Rapid
rogression of intimal thickness of more than 0.5 mm
uring the first year is a powerful predictor of all-cause
ortality, myocardial infarction, and later angiographic
bnormalities (81). Management of allograft vasculopathy
ocuses on the aggressive management of risk factors such as
yperlipidemia and the use of proliferation signal inhibitors
uch as sirolimus, which has been shown in a small study to
ecrease the progression of allograft vasculopathy (48,82).
tatin therapy has also been recently shown to have sus-
ained survival benefits at 10 years associated with a decrease
n allograft vasculopathy (83,84). Although antiplatelet
gents are commonly used, their efficacy has never been
learly established. Percutaneous revascularization of allo-
raft vasculopathy is often considered for focal lesions, but
he benefits of the procedure are limited by the diffuse
ature of the disease (85). Retransplantation is also consid-
red in selected patients with severe allograft vasculopathy. mhe Changing Face
f Infections in Heart Transplantation
nfection remains an important cause of mortality after
eart transplantation (5,86). In general, the risk of
nfection changes over time in a somewhat predictable
attern (87). Infections in the early period post-
ransplant (1 month) are mainly associated with tech-
ical or nosocomial factors; infection between 1 and 6
onths are often associated with opportunistic organisms
r activation of latent infection; infections after 6 months
re more often community acquired (87). Several factors
re contributing to the changing face of infection in solid
rgan transplantation: 1) the introduction of bacterial
nd viral prophylaxis (most often with trimethoprim-
ulfamethoxazole and valgancyclovir); 2) early withdrawal
f corticosteroids; 3) the emergence of more effective
ntifungal agents; and 4) the emergence of resistant
trains of bacteria and viruses. The major effects of
acterial and viral prophylaxis have been the significant
ecrease in pneumocystis pneumonia infection, infection
ith herpesviruses (e.g., cytomegalovirus), as well as a
ecrease in infections with listeria, nocardia, and toxoplas-
osis. The survival of patients with invasive aspergillus has
lso improved with the introduction of echinocandins (e.g.,
aspofungin) and new azoles (e.g., voriconazole or posicon-
zole) (88). In the future, more sensitive microbiological
ssays and better immune monitoring tools will hopefully
ontinue to decrease the mortality of infectious complica-
ions in solid organ transplant recipients (87).
he Changing Face of Malignancies
alignancies represent the leading cause of death among
ong-term survivors and equals cardiac allograft vasculopa-
hy as a cause of death in recipients who live longer than 5
ears (5). The 2 most important malignancies are post-
ransplant lymphoproliferative disorders and aggressive
kin cancers. Solid organ recipients at high risk for
ost-transplant lymphoproliferative disorder include
pstein-Barr virus seronegative patients, especially if
hey receive a seropositive donor, nonrenal transplants,
ore aggressive maintenance immunosuppression, and
ounger patients (89). There also exists a probable link
etween lymphoproliferative disease and OKT3 induc-
ion therapy (42). The incidence of skin cancer is
xpected to increase with the increasing age of recipients.
ajor advances in the treatment of cancer in heart
ransplant recipients include the introduction of prolif-
ration signal inhibitors, which slow the progression of
nd may even lead to the regression of some malignan-
ies, as well as advances in the treatment of lymphomas
such as rituximab) or invasive skin cancers (such as Mohs
icrographic surgery) (42,89).
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he incidence of RF after heart transplantation is also
xpected to increase as the recipient population becomes
lder and sicker. Severe RF after heart transplantation is a
isk factor for both short- and long-term mortality (5).
everal recent studies have established risk factors associated
ith both acute and chronic RF. Boyle et al. (90) recently
escribed risk factors for acute RF after heart transplanta-
ion. In their large retrospective study, acute RF requiring
ialysis occurred in 5.8% of patients and was associated with
ncreased mortality and length of hospital stay (89). Mul-
ifactorial analysis identified pre-transplant creatinine,
nsulin-requiring diabetes mellitus, hypoalbuminemia, and
uration of bypass as predictive of severe acute RF. The
ost common cause of chronic RF after heart transplanta-
ion is CNI toxicity. Other causes include graft failure,
ephrotoxic antimicrobials, or medication interactions that
nadvertently increase the levels of CNIs. Established risk
actors for chronic RF include increasing recipient age,
iabetes mellitus, pre-transplant RF, post-operative acute
F, and HLA hypersensitization (91,92). The CNI-free
egimens combining sirolimus and mycophenolate mofetil
ave recently been shown to improve renal function without
ncreasing the risk of rejection when initiated several years
fter transplantation (52,53).
olerance Induction
rogress toward achieving clinical tolerance, the holy grail
f transplantation, has been slow but steady over the last 4
ecades (93). Tolerance refers to a state of permanent
mmunological acceptance of the graft (in this case the
eart) without the need for ongoing immunosuppression
eyond the peri-transplantation period (94). Tolerance also
mplies preserved immunological response to new or previ-
usly encountered immune challenges (94). Achieving tol-
rance would considerably reduce the complications associ-
ted with chronic immunosuppression. One of the ongoing
ifficulties in studying tolerance at this time is the lack of
pecific markers of tolerance (70). Also, importantly, induc-
ng tolerance in heart transplantation may be inherently
ifferent than inducing tolerance in kidney transplantation.
his may be related to differences in the number of HLA
ismatches or different intensity or type of alloimmune
esponse between different organs (70,94,95). Successful
nduction of clinical tolerance in renal transplantation has
ainly relied on concurrent stem cell transplantation and
he achievement of mixed bone marrow chimerism (96,97).
ecause heart transplantation usually involves no HLA
atching, such chimerism induction would require potent
blation of the recipient bone marrow, significant radiation
xposure, and ongoing immunosuppression (94). Therefore,
t this time clinical trials of mixed chimerisms in heart
ransplantation do not seem justified. Promising approaches
nvolving peripheral tolerance induction in heart transplan-ation using monoclonal antibodies or fusion proteins to
nhibit costimulation and T cell activation are currently
eing studied (94).
onclusions
eart transplantation continues to offer patients with end
tage heart failure a chance for a better quality and length of
ife. Over the last 4 decades, a better understanding of the
lloimmune response has led to improved monitoring of
ejection and the development of better immunosuppressive
egimens. In the future, advances in immunosuppression
rotocols, organ preservation, and the use of more specific
mmune monitoring tools are likely to lead to significant
mprovements in outcomes. Maybe one day, achievement of
he holy grail of transplantation, immune tolerance, will
ventually open the door to normal lives and life spans for all
ransplant recipients.
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